Compares venetoclax with decitabine to chemotherapy in older adults with acute myeloid leukemia
Uses patient records and an AI model to compare two treatments in older leukemia patients.
Plain-language title generated from the registry record
Registry title: Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
Key facts
- Where
- Brescia, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07420790, who can take part
Where in Italy
- USD TMO AdultiBrescia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- Trial code
- NCT07420790
- Record updated
- 30 April 2026
- Original description
To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between ≥ 60 and < 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a matched control cohort of same AML patients treated with intensive chemotherapy.Read full original descriptionShow less
Designing a Generative AI Model and Propensity Score Matching Methodology for Validation of "The Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) in Elderly (e60 <75years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Eligible for Allogeneic Stem Cell Transplantation (Allo-SCT)". Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between ≥ 60 and < 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a matched control cohort of same AML patients treated with intensive chemotherapy.
In addittion, to further validate the efficacy of the VEN-DEC treatment approach in elderly AML patients, an advanced generative AI model will be constructed and trained using the historical cohort data. The AI model aims to simulate outcomes based on the standard
Inclusion: Patients with AML treated with cht (historical cohort) or VenDec (experimental cohort).
Exclusion: -.